Cargando…

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia

Detalles Bibliográficos
Autores principales:	Joshi, Sunil K., Keck, Jamie M., Eide, Christopher A., Bottomly, Daniel, Traer, Elie, Tyner, Jeffrey W., McWeeney, Shannon K., Tognon, Cristina E., Druker, Brian J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515826/ https://www.ncbi.nlm.nih.gov/pubmed/32366937 http://dx.doi.org/10.1038/s41375-020-0844-7

Ejemplares similares

HitWalker: variant prioritization for personalized functional cancer genomics
por: Bottomly, Daniel, et al.
Publicado: (2013)

A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia
por: Damnernsawad, Alisa, et al.
Publicado: (2020)

Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia
por: Kurtz, Stephen E., et al.
Publicado: (2022)

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

HitWalker2: visual analytics for precision medicine and beyond
por: Bottomly, Daniel, et al.
Publicado: (2016)

Immune cell proportions correlate with clinicogenomic features and ex vivo drug responses in acute myeloid leukemia
por: Romine, Kyle A., et al.
Publicado: (2023)

Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine
por: Bottomly, Daniel, et al.
Publicado: (2013)

Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
por: Rice, William G., et al.
Publicado: (2022)

plethy: management of whole body plethysmography data in R
por: Bottomly, Daniel, et al.
Publicado: (2015)

Comprehensive molecular characterization of a rare case of Philadelphia chromosome–positive acute myeloid leukemia
por: Rosenberg, Mara W., et al.
Publicado: (2022)

Identification of β-catenin binding regions in colon cancer cells using ChIP-Seq
por: Bottomly, Daniel, et al.
Publicado: (2010)

FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells
por: Javidi-Sharifi, Nathalie, et al.
Publicado: (2019)

Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells
por: Javidi-Sharifi, Nathalie, et al.
Publicado: (2019)

Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations
por: Yenerall, Paul, et al.
Publicado: (2021)

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
por: Oyogoa, Emmanuella, et al.
Publicado: (2023)

Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date
por: Fletcher, Luke, et al.
Publicado: (2020)

Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations
por: Zhang, Haijiao, et al.
Publicado: (2017)

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia
por: Watanabe-Smith, Kevin, et al.
Publicado: (2016)

Detection of Expression Quantitative Trait Loci in Complex Mouse Crosses: Impact and Alleviation of Data Quality and Complex Population Substructure
por: Iancu, Ovidiu D., et al.
Publicado: (2012)

Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma
por: Thieme, Elana, et al.
Publicado: (2022)

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
por: Zhang, Haijiao, et al.
Publicado: (2019)

Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia
por: Lamble, Adam J., et al.
Publicado: (2020)

Predicting response to BET inhibitors using computational modeling: A BEAT AML project study
por: Drusbosky, Leylah M., et al.
Publicado: (2019)

Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
por: Gao, Lina, et al.
Publicado: (2013)

Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3 mutation-positive leukemia
por: Agarwal, Anupriya, et al.
Publicado: (2014)

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
por: Rosenberg, Mara W., et al.
Publicado: (2020)

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
por: Choi, Byung-Kwon, et al.
Publicado: (2012)

Evaluating Gene Expression in C57BL/6J and DBA/2J Mouse Striatum Using RNA-Seq and Microarrays
por: Bottomly, Daniel, et al.
Publicado: (2011)

Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML
por: Gosline, Sara J. C., et al.
Publicado: (2022)

Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent
por: Leonard, Jessica T., et al.
Publicado: (2016)

A Single-Cell Approach to the Elusive Latent Human Cytomegalovirus Transcriptome
por: Goodrum, Felicia, et al.
Publicado: (2018)

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples
por: Edwards V, David K., et al.
Publicado: (2018)

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia
por: Bandyopadhyay, Shovik, et al.
Publicado: (2017)

The Mysterious Ways of ErbB2/HER2 Trafficking
por: Bertelsen, Vibeke, et al.
Publicado: (2014)

Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib
por: Vigoda, Myles, et al.
Publicado: (2022)

Quantitative Trait Locus Analysis: Multiple Cross and Heterogeneous Stock Mapping
por: Hitzemann, Robert, et al.
Publicado: (2008)

Revisiting NTRKs as an emerging oncogene in hematological malignancies
por: Joshi, Sunil K., et al.
Publicado: (2019)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia
por: Khanna, Vishesh, et al.
Publicado: (2015)

Prognostic value of ErbB2/HER2 in human meningiomas
por: Arnli, Magnus B., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_97qg1hfqaalrpdghsrrrr8n62r